Sp349association of Race/Ethnicity With Erythropoietin Stimulating Agent Use and Resistance in Hemodialysis Patients

Okoro, Tony; Carroll, Charlotte F.; Chao, Jessica; Laurent, Samantha St.; Shannon, Jennifer; Clifton, Christine S; Amelio, Justyna; Dickinson, Harriet

doi:10.1093/ndt/gfz103.sp349

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Race was noted as a risk factor for ESA unresponsiveness in an observational study on 20,516 patients receiving HD by Okoro et al [30] though this association is not significant when taking age, gender, and dialysis vintage into account in a multivariate model. Further work is required to evaluate ESA hyporesponsiveness across various health systems internationally and the impact of socioeconomic factors on this.…”

Section: Prevalence Of Esa Hyporesponsiveness In Ckdmentioning

confidence: 99%

Erythropoietin-Stimulating Agent Hyporesponsiveness in Patients Living with Chronic Kidney Disease

Chinnadurai

2022

Kidney Dis

View full text Add to dashboard Cite

Background: Erythropoietin-stimulating agent (ESA) hyporesponsiveness is commonly observed in patients with anemia secondary to chronic kidney disease (CKD). Because of its complexity, a global consensus on how we should define ESA hyporesponsiveness remains unavailable. The reported prevalence and demographic information on ESA hyporesponsiveness within the CKD population are variable with no consensus definition. Summary: ESA hyporesponsiveness is defined as having no increase in hemoglobin concentration from baseline after the first month of treatment on appropriate weight-based dosing. The important factors associated with ESA hyporesponsiveness include absolute or functional iron deficiency, inflammation, and uremia. Hepcidin has been demonstrated to play an important role in this process. Mineral bone disease secondary to CKD and non-iron malnutrition among other factors are also associated with ESA hyporesponsiveness. There is continued debate toward determining a gold-standard treatment pathway to manage ESA hyporesponsiveness. The development of hypoxia-inducing factor-stabilizers brings new insights and opportunities in the management of ESA hyporesponsiveness. Key Message: Management of ESA hyporesponsiveness involves a comprehensive multidisciplinary team approach to address its risk factors. The progression of basic and clinical research on identifying risk factors and management of ESA hyporesponsiveness brings greater hope on finding solutions to eventually tackling one of the most difficult problems in the topic of anemia in CKD.

show abstract

Section: Prevalence Of Esa Hyporesponsiveness In Ckdmentioning

confidence: 99%

Erythropoietin-Stimulating Agent Hyporesponsiveness in Patients Living with Chronic Kidney Disease

Chinnadurai

2022

Kidney Dis

View full text Add to dashboard Cite

show abstract

Sp349association of Race/Ethnicity With Erythropoietin Stimulating Agent Use and Resistance in Hemodialysis Patients

Cited by 1 publication

References 0 publications

Erythropoietin-Stimulating Agent Hyporesponsiveness in Patients Living with Chronic Kidney Disease

Erythropoietin-Stimulating Agent Hyporesponsiveness in Patients Living with Chronic Kidney Disease

Contact Info

Product

Resources

About